Adicet Bio (NASDAQ: ACET) grants 72,555 stock options to Chief Scientific Officer

Rhea-AI Filing Summary

Adicet Bio, Inc. Chief Scientific Officer Aftab Blake received a grant of stock options to acquire 72,555 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036.

According to the vesting terms, 1/48th of the options vest on each monthly anniversary over the next forty-eight months, as long as Blake continues a service relationship with the company. This is a compensation-related award, not an open-market purchase or sale, and it brings Blake’s directly held option position in this grant to 72,555 derivative securities.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Aftab Blake

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	72,555	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 72,555 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aftab Blake

(Last) (First) (Middle)

C/O ADICET BIO, INC.

131 DARTMOUTH STREET, FLOOR 3

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adicet Bio, Inc. [ ACET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.81	03/25/2026		A		72,555		(1)	03/24/2036	Common Stock	72,555	$0.00	72,555	D

Explanation of Responses:

1. (1) 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

	/s/ Nick Harvey, Attorney-in-Fact	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Adicet Bio (ACET) report for Aftab Blake?

Adicet Bio reported a stock option grant to Chief Scientific Officer Aftab Blake for 72,555 shares of common stock. The options are a compensation award, not a market trade, and give the right to buy shares at a fixed exercise price of $6.81.

What are the key terms of Aftab Blake’s stock options at Adicet Bio (ACET)?

The grant covers 72,555 options with an exercise price of $6.81 per share, expiring on March 24, 2036. The options represent the right, but not obligation, to buy Adicet Bio common stock at that price before expiration.

How do Aftab Blake’s Adicet Bio (ACET) stock options vest over time?

The options vest in 48 equal monthly installments. One forty-eighth of the 72,555 options vests on each monthly anniversary of the grant date, provided Blake maintains a service relationship with Adicet Bio on the applicable vesting dates.

Is Aftab Blake’s Form 4 transaction in Adicet Bio (ACET) a stock purchase or sale?

The Form 4 shows an option grant, not a purchase or sale. Code “A” reflects a grant or award of derivative securities as compensation, giving Blake rights to future share purchases instead of recording an immediate open-market buy or sell.

How many Adicet Bio (ACET) options does Aftab Blake hold after this grant?

Following this transaction, Blake holds 72,555 options related to this grant, all reported as directly owned. These options are tied to an equal number of underlying common shares, subject to the four-year monthly vesting schedule and the stated exercise price.